Study wrapper · #733
Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models.
Editor's note
This proof-of-concept study sought an optimal cardioprotective dose of MOTS-c in isolated rat hearts subjected to ischaemia-reperfusion, supported by molecular docking. Researchers report that 0.5 mg/kg gave maximal protection, a 73% reduction in infarct size versus injury alone, with improved haemodynamics, lower lactate dehydrogenase release, boosted antioxidant defences, and downregulated pro-apoptotic genes. The dose-response framing is genuinely useful for the field. But this is an ex vivo, single-model study; the authors themselves flag the lack of systemic influences and limited dose range, and call for pharmacokinetic and broader dosing work. These are preclinical findings; human data are needed before any clinical conclusions. It strengthens the animal cardioprotection signal while being refreshingly explicit about its own limits.
Plain-language abstract
Researchers wanted to find the best protective dose of MOTS-c, a mitochondria-derived peptide, for heart injury caused by restoring blood flow after a blockage. They used rat hearts kept beating outside the body, cut off flow for 30 minutes, then restored it while giving different MOTS-c doses, and also ran computer models of how MOTS-c interacts with key proteins. A dose of 0.5 mg/kg gave the strongest protection, cutting the damaged (infarct) area by about 73% compared with untreated injury, while improving the heart's pumping, reducing a cell-damage marker by 65%, strengthening antioxidant defences, and dialing down cell-death genes. The computer analysis suggested MOTS-c binds several survival-related proteins. The authors were clear about limits: this was an isolated-heart model without the rest of the body, and the dose range was narrow, so more dosing and drug-behaviour studies are needed. Being done only in animals, it cannot yet inform treatment in people.